Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739644 | 0.90 | MEN1 (0.56) | MEN1KMT2AKDM4EDHODHIGF2BP2 | |
| SCHEMBL29739233 | 0.85 | RAB9A (0.56) | MEN1KMT2AKDM4EDHODHIGF2BP2 | |
| SCHEMBL20565746 | 0.84 | KMT2A (0.53) | MEN1KMT2AKDM4EDHODHIGF2BP2 | |
| SCHEMBL16907611 | 0.83 | MEN1 (0.53) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL16907381 | 0.83 | RAB9A (0.56) | MEN1KMT2AKDM4EDHODHIGF2BP2 | |
| SCHEMBL29739710 | 0.82 | KMT2A (0.53) | MEN1KMT2AKDM4EDHODHIGF2BP2 | |
| SCHEMBL11184124 | 0.80 | NPC1 (0.63) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL1322757 | 0.79 | TRPV1 (0.60) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL4459580 | 0.78 | CYP1A2 (0.61) | KMT2AKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4351772 | 0.77 | EPHX2 (0.63) | MEN1KMT2AKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | disclosed |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-05-04 | — | — | US | disclosed |
| EP-3157924-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | disclosed |
| CN-106559992-A | As the bicyclic heteroaromatic derivative for condensing of kinase inhibitor | UCB生物制药私人有限公司 | 2017-04-05 | — | — | CN | disclosed |
| WO-2015193169-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | MEN1 3527/4885KMT2A 1942/4885KDM4E 1050/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | MEN1 3527/4885KMT2A 1942/4885KDM4E 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.